Europe Approves ANKTIVA: First Immunotherapy for Hard-to-Treat Bladder Cancer Now in 33 Countries

ImmunityBio’s ANKTIVA + BCG just received European Commission approval – the first new immunotherapy in Europe for hard-to-treat bladder cancer. Now available in 33 countries, offering hope without surgery.